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Beta amyloid peptide (A) is the major proteinaceous component of senile plaques formed in
Alzheimer’s disease (AD) brain. The aggregation of A is associated with neurodegeneration,
loss of cognitive ability, and premature death. It has been suggested that oxidative stress and
generation of free radical species have implications in the fibrillation of A and its subsequent
neurotoxicity. For this reason, it is proposed that antioxidants may offer a protective or
therapeutic alternative against amyloidosis. This study is the first report of the formation of the
noncovalent complex between A or its oxidized form and the natural derived antioxidant
oleuropein (OE) by electrospray ionization mass spectrometry (ESI MS). ESI MS allowed the
real time monitoring of the complex formation between A, OE, and variants thereof. Several
experimental conditions, such as elevated orifice potential, low pH values, presence of organic
modifier, and ligand concentration were examined, to assess the specificity and the stability of
the formed noncovalent complexes. (J Am Soc Mass Spectrom 2006, 17, 568–575) © 2006
American Society for Mass SpectrometryAlzheimer’s disease (AD) is the most commonform of senile dementia, which affects a greatpart of the world’s population, with no cure yet
known. Even though the cause of AD remains un-
known, the formation of the amyloid  peptide contain-
ing plaques and the tau ()-protein containing neurofi-
brillary tangles are the main hypotheses that have
prevailed [1]. Human AD neuritic plaques consist
mainly of deposited  amyloid peptide (A) [2], which
derives from the proteolytic cleavage of the amyloid
precursor protein (APP). Spontaneous conformational
changes of A lead to the formation of toxic protofibril-
lar intermediate species, rich in -sheet, that convert to
mature fibrils and eventually plaques [3]. The formation
of the aforementioned fibrils is initiated by a multitude
of risk factors, with oxidative stress and generation of
free radicals being the main mechanisms [4]. Reactive
oxygen species (ROS) can cause protein and lipid oxi-
dation, which leads to loss of ion homeostasis and cell
death, and are related to the aggregation and neurotox-
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doi:10.1016/j.jasms.2005.11.016icity of A [5]. Even if ROS are a consequence rather
than a cause of A aggregation [6], the fact that oxida-
tive stress can result in neurodegeneration and cell
death [7] suggests that free radical scavengers [8] may
be beneficial as a therapeutic and/or preventive ap-
proach against AD. In light of the suggested link
between oxidative stress, inflammatory response [9]
and AD, anti-inflammatory agents [10] have been em-
ployed as therapeutic approaches against AD, because
A has been shown to stimulate macrophages and
microglia. Other therapeutic alternatives include inhi-
bition of amyloid formation by controlling APP proteo-
lytic cleavage [11, 12], control of A degradation [13],
immunization with A [14, 15], and inhibition of A
aggregation or disaggregation of A deposits. The last
involves binding of small molecules [16, 17] to A,
which stabilize its structure, thus becoming potential
inhibitors of amyloidosis. Approaches like this are
being studied as therapeutic alternatives for disorders
like AD [18], Creutzfeldt Jakob disease [19], and diabe-
tes type II [20]. It is noteworthy that antioxidants, such
as melatonin, have shown to form noncovalent com-
plexes with A [21] and exhibit anti-amyloidogenic
properties.
Plants containing antioxidants and phytoestrogens,
and more specifically substances with phenolic struc-
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estradiol, have been involved in the management of
cognitive disorders such as AD [22]. In vitro [23] and
epidemiological [24] studies pointed out the positive
impact of natural extracted polyphenols on the inci-
dence of age-related disorders, such as dementia. In this
study, oleuropein (OE) (Figure 1), a bioactive polyphe-
nol extracted from the fruits and leaves of Olea Europea
L., was evaluated towards the decrease or even preven-
tion of A aggregation, which is inherent to AD. OE has
been shown to possess a broad range of biochemical
and beneficial pharmacological properties, such as an-
tioxidant [25], anti-inflammatory [26], antiatherogenic
[27], antibacterial [28], and anticancer [29]. The potential
effect of OE on the brain function may be attributable, at
least in part, to its significant cardioprotective effects. It
has been reported that AD is analogous to atheroscle-
rosis, because they both are age-dependent diseases in
which abnormal accumulation of a normal metabolite
(cholesterol and A, respectively) precedes clinical
symptoms and leads to disease [30, 31]. The link be-
tween heart disease, hypercholesterolemia, and AD [32]
may involve similar mechanisms in the pathogenesis of
these disorders. The circumstantial evidence that cho-
lesterol-related interventions can alter A deposition
[33, 34], suggest that OE could be promising in the
management of AD. Furthermore, the importance of
inflammatory processes in the clinical manifestation of
AD [9, 35], combined with the epidemiological evidence
of a protective effect of anti-inflammatory agents [36]
against AD, suggest that a polyphenolic natural extract,
Figure 1. Molecular structure of oleuropein (OE). The molecule
is a glucoside consisting of a glucose unit (A) and a moiety called
oleuropein aglycon (B). The latter consists of two chemical sub-
units, the polyphenolic part hydroxytyrosol (C), and the lactone
part elenolic acid (D).such as OE, could prove effective against age-dependent disorders such as AD. Furthermore, it has
been reported that OE and its metabolites could be
potent bioactive compounds against contemporary dis-
eases, such as HIV [37], osteoporosis [38], and AD [39].
The aim of the present study was the establishment
of the noncovalent interaction between A (1-40) and
OE by means of electrospray ionization (ESI) mass
spectrometry. Mass spectrometry (MS) is a powerful
tool for analyzing the primary structure of biomolecules
and especially for monitoring their interactions [40]. In
general, noncovalent interactions between proteins/
peptides and ligands may be involved in triggering
diseases. Thus, the elucidation of the structure and the
formation mechanism of noncovalent complexes be-
tween proteins and ligands may lead to a better under-
standing of a disease process and the development of a
therapeutic approach [41]. This is the first report of
detecting noncovalent complexes between A and nat-
urally occurring compounds by ESI MS. The effect of
OE concentration, solution pH and organic modifier
content on the stability and specificity of the noncova-
lent interaction, as well as the possible effect of time on
the conformation and aggregation of A, in the pres-
ence or absence of OE, is also discussed.
Experimental
Sample Preparation
A 150 L aliquot of a freshly prepared A (1-40)
solution 100 M (Mr 4329.9; Bachem AG, Bubendorf,
Switzerland) in deionized water was added into 150 L
of an equimolar OE solution, (Mr 540.5) in 1 mM
ammonium acetate- (Merck, Darmstad, Germany) ace-
tic acid 0.5%. OE was isolated from the leaves of Olea
europea var. koroneiki, according to a previously de-
scribed procedure [42] with greater than 99% purity, as
it was assessed by NMR analysis. All solvents used
were of analytical grade purity.
The prepared solutions were directly infused after 1
min vortexing, or analyzed after incubation at room
temperature for 1 h, 3.5 h, 3 days, 5 days, 9 days, and 25
days. In another aliquot of the A (1-40) solution an
equal volume of the acetate buffer was added, whereas
an equal volume of deionized water was added in an
aliquot of the OE solution in acetate buffer and ana-
lyzed at each time interval. The stability of A and OE
under the experimental conditions was also checked.
Post addition of OE in equimolar ratio to already aged
A solutions was also performed.
Mass Spectrometry
A Sciex API-III triple quadrupole instrument equipped
with a standard atmospheric pressure ionization source
(Sciex, Concord, ON, Canada) was used in the positive
ion mode. Sample solution was directly infused at a
flow rate of 5 L/min using a Harvard syringe pump.
A standard PPG solution was used for tuning and mass
vely,
570 BAZOTI ET AL. J Am Soc Mass Spectrom 2006, 17, 568–575calibration. The scanning mass range of the mass spec-
trometer was 300–1500 Da at a rate of 5000 Da/min at
a step size of 0.5 Da. The acquired mass spectra were the
average of 20–40 scans. Needle potential was set at 4000
V and the OR potential at 35 V. The curtain and
nebulizer gas flow rates were 1.0 and 0.4–0.8 L/min,
respectively.
Results and Discussion
ESI MS is a gentle ionization method, which allows the
preservation of the fragile noncovalent interactions in
the gas-phase provided careful optimization of the
instrumental parameters. Therefore, ESI MS analysis
represents an ideal approach to provide the Mr of the
noncovalent complexes formed in solution, as well as
the stoichiometry of the interacting species.
ESI-MS Analysis of A and A-OE
ESI mass spectrometric analysis of the A (1-40) solu-
tion (Figure 2a) revealed a multiply charged ion enve-
lope including signals at m/z 722.5 (6), 867.0 (5),
1083.5 (4), and 1444.0 (3). An average mass (Mr) of
4330.0 is derived after deconvolution of the raw ESI MS
data (Figure 2a, inset), which correlates well with the
theoretical value of 4329.9. ESI MS analysis of the A
solution containing OE generated a spectrum including
the aforementioned A envelope and a “bell-shaped”
distribution of multiply charged ions at m/z 812.0, 975.0,
and 1218.5 (Figure 2b), which corresponded to the 6,
Figure 2. ESI mass spectra of (a) amyloid- pep
its mixture with oleuropein (1:1 molecular rati
analyzer. The deconvoluted spectra of the A
measured Mr values 4330.0 and 4870.0, respecti5, and 4 charge states of the 1:1 A:OE noncovalentcomplex, respectively. Deconvolution of the observed
ion envelope gave rise to an Mr of 4870.0, which is in
good agreement with the theoretical average mass of
4870.4 for the 1:1 A:OE noncovalent complex (Figure
2b, inset). Thus, the electrospray ionization process and
the experimental conditions maintained the existing
interactions in solution, thereby showing that OE forms
noncovalent complexes with Awith 1:1 stoichiometry.
Parameter Optimization for the A-OE
Noncovalent Complex Monitoring
The binding strength of the A-OE noncovalent com-
plex was tested under various critical conditions for its
formation and maintenance. The stability of the com-
plex, as well as nonspecific aggregation, can be assessed
by calculating the ratio of the complex ion envelope
intensity plots versus that of the peptide ion envelope in
the spectrum (Figure 3). It is known that conformational
changes of the peptide and denaturation of proteins
occur in the presence of organic modifiers [43] or at low
pH values. It is also known that nonspecific aggregation
may occur at higher concentrations of peptide/ligand.
Therefore, it was important to confirm that the A-OE
complex was the result of specific interactions. The
stability and specificity of the A-OE complex was
assessed by varying the OR potential, the pH of the
sample solution, the percentage of an organic modifier
in the spraying solution [44] (Figure 3), and the OE
(1-40) at a concentration level of 100 M and (b)
0 M), acquired by a triple quadrupole mass
ide and the A-OE noncovalent complex with
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The collisional excitation effect of the ion-sampling
interface may be incorporated to qualitatively study the
binding strength of the peptide-ligand noncovalent
complex. Elevating the OR potential, increases the in-
ternal energy of the noncovalent complex, which in turn
affects its conformation and consequently can result in
the dissociation of the complex. The energy required for
breaking these complexes apart depends on the binding
energy of the noncovalent interaction and may serve as
an indication for the gas-phase complex stability and
furthermore, as an indication for the solution phase
noncovalent interactions.
The binding strength of the A-OE noncovalent
interaction was studied at OR potential settings ranging
from 35 to 100 V (35, 50, 70, 80, and 100 V) (Figure 3a
and b). In the ESI mass spectrum of the A-OE solution,
an increase in the OR potential shifted the A peptide
“bell-shaped” envelope to higher m/z values due to
charge stripping. From 35 up to 70 V, the central charge
state of the envelope was5, while it shifted to4 at 80
V and to 3 at 100 V (Figure 3a). In the ESI mass
spectrum of A-OE, an increase in the OR potential
from 35 to 50 V resulted in a slight decrease of the
signals corresponding to A and A-OE, whereas the
Figure 3. Relative signal intensity dissociation
complex with oleuropein (b, d, and f) in equimo
pH (c and d) and % of organic modifier in the
different charge states of the A or the A-OE i
ratio of the signal intensity of each multiply c
abundant peak in the spectrum, i.e., A (5) ser
charged states with increase in the OR potentiaA-OE signals were still present at OR potential values80 V. The multiply charged ion envelope of the
A-OE complex shifted to higher m/z values at 80 V and
it was centered around the 4 charge state (Figures 3b
and 4). At 100 V, the 4 charge state of the A-OE
complex could still be detected. The ratio of the [com-
plexed:free] peptide slightly decreased with increasing
OR potential values, i.e., from 0.23 (35 V) to 0.17 (80 V),
thus indicating the strong stability of the complex
(Figure 4).
Solution pH Effect on A-OE Interaction
It is well established that the ESI process in the positive ion
mode is more effective when using samples with low pH
values because of a more efficient protonation and forma-
tion of multiply charged species. On the other hand,
extreme basic or acidic pH values of a solution may
denature a protein from its native conformation, which in
turn may disrupt noncovalent interactions. Protein un-
folding induced by low pH values can be revealed inmass
spectra because of extensive protonation of the basic
amino acids of a protein (e.g., Lys, Arg, His), which are
easily accessed in the “open” conformation [44].
The stability of the A-OE noncovalent complex was
studied as a function of the sample solution pH (Figure
ves for A (1-40) peptide (a, c, and e) and its
atio, as a function of orifice potential (a and b),
le (e and f). Each trend line corresponds to the
velope. Relative intensity was calculated as the
ed ion versus the signal intensity of the most





ving3c and d). The solvent pH was adjusted from 5.7 to 4.2,
572 BAZOTI ET AL. J Am Soc Mass Spectrom 2006, 17, 568–5753.0, and 2.5 by adding glacial acetic acid. Increase of the
pH shifted the A ion envelope to higher m/z values,
since fewer protons are available for the protonation of
the peptide (Figure 3c). On the other hand, lower pH
values shifted the A-OE ion envelope to lower m/z
values (Figure 3d), due to a more extensive protonation.
The ratio of the [complexed:free] peptide changed from
0.29 (pH 5.7) to 0.09 (pH 2.5) (Figure 5), which indicates
substantial unfolding of the peptide and subsequent
release of OE from its binding site at lower pH values.
Organic Solvent Percentage Effect on A-OE
Interaction
To efficiently generate gas-phase ions during the ESI
process, an organic co-solvent is usually added to
enhance evaporation of the charged droplets. The pres-
ence of an organic solvent, like methanol or acetonitrile,
and the medium pH values needed for protonation
enhance the ESI sensitivity and the ion signal stability.
However, the addition of organic solvents may disrupt
the tertiary structure of a protein or peptide and result
in a more extended conformation, where a higher
number of basic amino acids are available for protona-
tion, as it was the case in low pH values. It should be
mentioned that to maintain noncovalent interactions,
Figure 4. Deconvoluted ESI mass spectra of amyloid- peptide
(1-40) in a mixture with oleuropein in 1:1 molecular ratio (concen-
tration level 100 M) analyzed under different orifice potential
values: (a) 35 V, (b) 50 V, and (c) 80 V. The slight decrease of the
[complexed:free] peptide ratio (0.23, 0.19, and 0.17, respectively)
with increasing orifice potential values indicates the high binding
energy of the A-OE noncovalent complex.the choice of solution conditions should be conserved as
close to the protein’s native-like solution environment
as possible.
The effect of the organic solvent content on the
preservation of the A-OE noncovalent complex has
been studied by preparing samples containing 0, 10, 45,
and 75% MeOH (Figure 3e and f). The ratio of the
[complexed:free] peptide changed from 0.25 (10%
MeOH) to 0.40 (45% MeOH) (Figure 6). It was found
that addition of 45%MeOHwas optimum for observing
higher abundance of the complex-derived signals, ap-
parently due to better ESI ionization (Figures 3f and 6).
Nevertheless, the A-OE noncovalent complex is effi-
ciently conserved even at extreme MeOH content val-
ues, i.e., 75%, even though the S/N of the ESI signals
decreases and new peaks appear in the mass spectrum
because of partial hydrolysis of the peptide (Figure 6c).
Solute Concentration Effect on A-OE Interaction
Nonspecific complexes may be formed as artifacts of the
ESI process. The prevalence of nonspecific aggregation
in the gas-phase may be avoided by increasing the
internal energy of the complex (e.g., by elevating the OR
potential), or by reducing the solution concentration of
Figure 5. Deconvoluted electrospray ionization mass spectra of
amyloid- peptide (1-40) in a 1:1 mixture with oleuropein (con-
centration level 100 M) at two different sample pH values: (a) 5.7
and (b) 2.5. The respective ratio of the [complexed:free] peptide
changes from 0.29 to 0.09, due to substantial unfolding of the
peptide and subsequent release of oleuropein from its binding site
at lower pH values.the interacting species. The specificity of the A-OE
573J Am Soc Mass Spectrom 2006, 17, 568–575 A–OLEUROPEIN NONCOVALENT COMPLEX FORMATIONnoncovalent interaction was evaluated at low concen-
tration levels ranging from 5 to 100 M (5, 10, 50, 100
M). The A:OE molecular ratio used was 1:1 at all
concentration levels and consistent results were ob-
tained, thus proving the specificity of the interaction.
Molecular excess of 10:1 in OE:A provided no differ-
ence in the stoichiometry of the complex, thus indicat-
ing a very specific interaction.
The presented data support that OE forms noncova-
lent complexes with A (1-40). The stoichiometry of the
complex (1:1) is not pH, organic solvent, or analyte
concentration dependent. The optimum values of pH,
OR potential, and % of organic modifier for the detec-
tion of the A-OE noncovalent complex were found to
be 4.2, 35 V, and 45%, respectively.
Time Effect on A-OE Interaction
The spontaneous aggregational propensity of A, as
well as its complex formation ability with OE, was
studied as a function of time. In this way, rapid equi-
librium was studied, as well as possible structural
modifications of the A-OE complex and the effect of
OE on A aggregation.
The ESI mass spectra of the A-OE samples included
satellite signals at higher m/z values of the 4, 5, and
Figure 6. Deconvoluted electrospray ionization mass spectra of
amyloid- peptide (1-40) in a mixture with oleuropein (1:1 molecular
ratio, concentration level 100 M) in samples containing: (a) 10%, (b)
45%, and (c) 75%MeOH as organic co-solvent. The abundance of the
A-OE noncovalent complex decreases at high percentages of or-
ganic modifier as a result of peptide denaturation. However, the
A-OE complex detection, even when the MeOH content increases
up to 75%, indicates the specificity and the stability of the formed
noncovalent complex.6 ion signals of the A peptide, and were detectedeven when the analyzed samples had been incubated
for some hours. These signals were consistent with the
oxidation of A at the methionine 35 (Met35) residue,
and they became more pronounced with time, as shown
in the deconvoluted spectrum of the 9- and 25-day old
samples (Figure 7a and 7b, Table 1). Deconvolution of
these ion signals gave rise to anMr of 4346.0, which agrees
well with the theoretical mass of 4345.9 for the Met35(O)-
containing A peptide (Aox). In addition, ESI signals
corresponding to the noncovalent complex of OE with the
oxidized form of A (Aox) were also detected. The
theoretical Mr of the 1:1 Aox-OE noncovalent complex
(4886.4, Table 1) agrees well with the corresponding value
derived from the deconvoluted spectrum of Aox-OE
(Figure 7). The ion signals corresponding to the oxidized
complex become more prominent with time, thus indicat-
ing an increase in the formation of the Aox component.
The ESI mass spectrum of the aged A sample is signifi-
cantly different than that of theA:OE sample. In themass
spectrum of the 25 day-old A sample the [A:Aox] ratio
is 2:1, while this ratio in the 25 day-old A:OE sample is
1:1. This indicates that the presence of OE renders the
Met35 residue more susceptible to oxidation in aged
samples. This may be significant in terms of its possible
role in attenuating the A oligomerization, as it has been
previously shown by Palmblad et al. [45]. The high
proportion of Met sulfoxide present in the senile plaques
[46] can be explained by the fact that the single Met35
residue of A is critical to a free radical process of A
toxicity to neurons [6]. Met participates in unusual free
radical reaction chemistry [47], and its oxidation leads to
conformational switching [48] and adaptation of the
-sheet conformation, which is responsible for the A
toxicity [49]. However, Aox was found to interact nonco-
valentlywithOE aswell. Therefore, a detailed study of the
topology of the binding is currently under way by map-
ping analysis of the detected A-OE noncovalent com-
plex.
It should be noted that no mass spectral signals
attributed to oligomers, besides dimers, have been
observed for samples incubated for 25 days. This is
possibly due to Met35 oxidation, or occupation of a big
surface of the peptide by OE, which blocks the oli-
gomerization more efficiently. However, it has been
reported that the aggregated forms of A become
weaker and ultimately absent in aged solutions as a
result of a conformational shift from random coil to the
more compact -sheet conformation [50].
Post-Addition of OE in Aged A Solution
In two aliquots of the 3-day old A solution an equal
volume of an equimolar OE solution and an equal
volume of mobile phase was added, respectively, the
latter being used as a control sample at this concentra-
tion level (0.05 mM). The samples were incubated for 2,
6, and 21 days at room temperature before analysis. In
this way, conclusions could be derived regarding the
inhibitory properties of OE on further fibrillation of A,
pecti
574 BAZOTI ET AL. J Am Soc Mass Spectrom 2006, 17, 568–575its possible disaggregational properties, or its ability to
form complexes not only with the monomers, but also
with oligomers or higher order polymers. This could be
attributed to different complex formation kinetics when
the addition of the analyte is performed directly in
freshly prepared A solution, than when performed in
A solutions already containing some aggregates. Nev-
ertheless, clear conclusions could not be drawn regard-
ing the effect of OE on the aggregation of A because no
mass spectral signals attributed to oligomers, besides
dimers, have been detected during the post-addition
study.
Figure 7. Electrospray ionization mass spectr
oleuropein (1:1 molecular ratio, concentration le
analyzer after incubation at room temperature fo
in the insets depict the presence of A (1-40) an
4330.0 and 4346.0, respectively, as well as their
with measured Mr values 4870.0 and 4886.0, res
Table 1. Theoretical and observed average mass values of the
A (1–40) peptide, its oxidized form A (1–40) ox and their




A (1–40) 4329.9 4330.0
A (1–40)ox 4345.9 4346.0
A (1–40)-OE 4870.4 4870.0
A (1–40)ox-OE 4886.4 4886.0Conclusions
This study demonstrates the utility of ESI MS in this
area of neuroscience research. The successful detection
of the noncovalent complex between A and OE could
be invaluable in a series of studies focused on screening
the ability of several bioactive phytochemicals in terms
of complexating A and Aox and “locking” them in a
non-toxic conformation, thus acting as potential anti-
amyloidogenic agents. This may offer an ideal protec-
tive alternative against A toxicity.
In conclusion, this ESI MS study shows that the
stoichiometry of the noncovalent complex between A
(1-40) and OE is neither pH nor organic modifier
sensitive. Even though the primary constituent of amy-
loid plaques is A (1-42) peptide, A (1-40) possesses a
high degree of homology to A (1-42) and is co-
localized with it in the neuritic plaque . The Met35(O)-
containing A (1-40) variant (Aox) was also found to
interact noncovalently with OE at 1:1 stoichiometry.
The preservation of the A-OE complex even at ex-
treme conditions (i.e., high percentage of organic co-
solvent or high OR values) is indicative of the high
binding energy of the A-OE interaction. The very high
f amyloid- peptide (1-40) in a mixture with
100 M) acquired by a triple quadrupole mass
days and (b) 25 days. The deconvoluted spectra
oxidized form Aox, with measured Mr values





respsensitivity of ESI MS-based methodologies enables the
575J Am Soc Mass Spectrom 2006, 17, 568–575 A–OLEUROPEIN NONCOVALENT COMPLEX FORMATIONrecognition of possible biomarkers useful in the diag-
nosis of this disease and may shed some light into the
mechanisms involved in AD pathology. Furthermore,
the presented ESI MS methodology enabling the direct
determination and real-time monitoring of all species in
equilibrium could provide insights into structural ana-
logs of OE with improved properties that may act as
potential anti-amyloidogenic agents.
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